TY - JOUR
T1 - Genomic classifications of renal cell carcinoma
T2 - a critical step towards the future application of personalized kidney cancer care with pan-omics precision
AU - Hsieh, James J.
AU - Le, Valerie
AU - Cao, Dengfeng
AU - Cheng, Emily H.
AU - Creighton, Chad J.
N1 - Publisher Copyright:
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
PY - 2018/4
Y1 - 2018/4
N2 - Over the past 20 years, classifications of kidney cancer have undergone major revisions based on morphological refinements and molecular characterizations. The 2016 WHO classification of renal tumors recognizes more than ten different renal cell carcinoma (RCC) subtypes. Furthermore, the marked inter- and intra-tumor heterogeneity of RCC is now well appreciated. Nevertheless, contemporary multi-omics studies of RCC, encompassing genomics, transcriptomics, proteomics, and metabolomics, not only highlight apparent diversity but also showcase and underline commonality. Here, we wish to provide an integrated perspective concerning the future ‘functional’ classification of renal cancer by bridging gaps among morphology, biology, multi-omics, and therapeutics. This review focuses on recent progress and elaborates the potential value of contemporary pan-omics approaches with a special emphasis on cancer genomics unveiled through next-generation sequencing technology, and how an integrated multi-omics approach might impact precision-based personalized kidney cancer care in the near future.
AB - Over the past 20 years, classifications of kidney cancer have undergone major revisions based on morphological refinements and molecular characterizations. The 2016 WHO classification of renal tumors recognizes more than ten different renal cell carcinoma (RCC) subtypes. Furthermore, the marked inter- and intra-tumor heterogeneity of RCC is now well appreciated. Nevertheless, contemporary multi-omics studies of RCC, encompassing genomics, transcriptomics, proteomics, and metabolomics, not only highlight apparent diversity but also showcase and underline commonality. Here, we wish to provide an integrated perspective concerning the future ‘functional’ classification of renal cancer by bridging gaps among morphology, biology, multi-omics, and therapeutics. This review focuses on recent progress and elaborates the potential value of contemporary pan-omics approaches with a special emphasis on cancer genomics unveiled through next-generation sequencing technology, and how an integrated multi-omics approach might impact precision-based personalized kidney cancer care in the near future.
KW - biomarkers
KW - genomics
KW - metabolomics
KW - personalized medicine
KW - precision therapeutics
KW - proteomics
KW - renal cell carcinoma
KW - targeted therapy
KW - transcriptomics
UR - http://www.scopus.com/inward/record.url?scp=85044317167&partnerID=8YFLogxK
U2 - 10.1002/path.5022
DO - 10.1002/path.5022
M3 - Review article
C2 - 29266437
AN - SCOPUS:85044317167
SN - 0022-3417
VL - 244
SP - 525
EP - 537
JO - Journal of Pathology
JF - Journal of Pathology
IS - 5
ER -